1. N02 Safety And Tolerability Of Selisistat For The Treatment Of Huntington's Disease: Results From A Randomised, Double-blind, Placebo-controlled Phase Ii Trial. (17th September 2014) Authors: Reilmann, R; Squitieri, F; Priller, J; Saft, C; Mariotti, C; Süssmuth, SD; Nemeth, AH; Tabrizi, SJ; Quarrell, O; Craufurd, D; Rickards, H; Rosser, A; Darpo, B; Tessari, M; Szynol, A; Fischer, DF; Frost, C; Farmer, RE; Landwehrmeyer, GB; Westerberg, G Journal: Journal of neurology, neurosurgery and psychiatry Issue: Volume 85(2014)Supplement 1 Page Start: A102 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Results From the IQ‐CSRC Prospective Study Support Replacement of the Thorough QT Study by QT Assessment in the Early Clinical Phase. Issue 4 (16th March 2015) Authors: Darpo, B; Benson, C; Dota, C; Ferber, G; Garnett, C; Green, CL; Jarugula, V; Johannesen, L; Keirns, J; Krudys, K; Liu, J; Ortemann‐Renon, C; Riley, S; Sarapa, N; Smith, B; Stoltz, RR; Zhou, M; Stockbridge, N Journal: Clinical pharmacology & therapeutics Issue: Volume 97:Issue 4(2015:Apr.) Page Start: 326 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Results From the IQ‐CSRC Prospective Study Support Replacement of the Thorough QT Study by QT Assessment in the Early Clinical Phase. Issue 4 (April 2015) Authors: Darpo, B; Benson, C; Dota, C; Ferber, G; Garnett, C; Green, CL; Jarugula, V; Johannesen, L; Keirns, J; Krudys, K; Liu, J; Ortemann‐Renon, C; Riley, S; Sarapa, N; Smith, B; Stoltz, RR; Zhou, M; Stockbridge, N Journal: Clinical pharmacology & therapeutics Issue: Volume 97:Issue 4(2015:Apr.) Page Start: 326 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗